Theriva Biologics 株価情報 (AMEX: TOVX)

最新ニュース Theriva Biologics (AMEX:TOVX) 株価情報

Theriva Biologics

Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.

Theriva Biologics Inc

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>JP Morgan analyst Samik Chatterjee downgraded the rating for Luminar Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAZR#NASDAQ">LAZR</a>) from Overweight to Neutral. Luminar shares closed at $4.76 on Wednesday. <a href="https://www.benzinga.com/quote/lazr/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Scotiabank analyst Greg McGinniss downgraded Americold Realty Trust, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COLD#NYSE">COLD</a>) from Sector Outperform to Sector Perform and announced a $20 price target. Americold Realty Trust shares closed at $17.94 on Wednesday. <a href="https://www.benzinga.com/quote/cold/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>UBS analyst Daniel Major downgraded the rating for Alcoa Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AA#NYSE">AA</a>) from Buy to Neutral and announced a $31 price target. Alcoa shares closed at $29.61 on Wednesday. <a href="https://www.benzinga.com/quote/aa/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>William Blair analyst Sami Corwin downgraded the rating for Nkarta, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTX#NASDAQ">NKTX</a>) from Outperform to Market Perform. Nkarta shares closed at $1.87 on Wednesday. <a href="https://www.benzinga.com/quote/NKTX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Telsey Advisory Group analyst Dana Telsey downgraded Grove Collaborative Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GROV#NYSE">GROV</a>) from Outperform to Market Perform and slashed the price target from $2 to $1.2. Grove Collaborative shares closed at $1.19 on Wednesday. <a href="https://www.benzinga.com/quote/GROV/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying AA stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="575" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/15080300/image-179-1024x575.png" alt="" class="wp-image-916381" style="width:623px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/15080300/image-179-1024x575.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/15080300/image-179-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/15080300/image-179-768x431.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/15080300/image-179.png 1125w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45405004/jim-cramer-sofi-goes-to-new-highs-recommends-not-buying-this-health-care-stock">Jim Cramer: SoFi Goes To &#8216;New Highs,&#8217; Recommends Not Buying This Health Care Stock</a> </li>
</ul>
Photo via Shutterstock

News

Downgrades

Pre-Market Outlook

Analyst Ratings

Trading Ideas

COLD

GROV

LAZR

NKTX

This Alcoa Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday

Fiscal 2025 Guidance
The Company is updating its expectations for fiscal 2025 revenue to be in the range of $29.0 to $31.0 million. The change in expectations is primarily due to expected continuing disruptions within the U.S. sorghum market due to decreased exports by customers to China and general market uncertainty. In fiscal 2024, comparable revenue from continuing operations was $38.0 million, which excludes revenue generated by the Company's former Australian subsidiary.&nbsp;
The Company now expects Adjusted EBITDA to be in the range of ($8.5) to ($7.0) million for fiscal 2025.

Guidance

SANW

S&W Seed Lowers FY2025 Sales Guidance from $34.50M-$38.00M to $29.00M-$31.00M vs $35.89M Est

Lifeward (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFWD#NASDAQ">LFWD</a>) affirms FY2025 sales outlook from $28.00 million-$30.00 million to $28.00 million-$30.00 million vs $28.98 million estimate.

LFWD

Lifeward Affirms FY2025 Sales Guidance of $28.00M-$30.00M vs $28.98M Est

S&amp;W Seed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SANW#NASDAQ">SANW</a>) reported quarterly losses of $(0.57) per share which beat the analyst consensus estimate of $(1.09) by 47.71 percent. This is a 68.16 percent increase over losses of $(1.79) per share from the same period last year. The company reported quarterly sales of $9.55 million which beat the analyst consensus estimate of $9.50 million by 0.53 percent. This is a 1.95 percent increase over sales of $9.37 million the same period last year.

Earnings

Earnings Beats

S&W Seed Q3 Adj. EPS $(0.57) Beats $(1.09) Estimate, Sales $9.55M Beat $9.50M Estimate

Rewalk Robotics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFWD#NASDAQ">LFWD</a>) reported quarterly losses of $(0.44) per share which missed the analyst consensus estimate of $(0.38) by 15.79 percent. This is a 29.03 percent increase over losses of $(0.62) per share from the same period last year. The company reported quarterly sales of $5.03 million which missed the analyst consensus estimate of $5.75 million by 12.51 percent. This is a 4.71 percent decrease over sales of $5.28 million the same period last year.

Earnings Misses

Rewalk Robotics Q1 Adj. EPS $(0.44) Misses $(0.38) Estimate, Sales $5.03M Miss $5.75M Estimate

WIIM

GSX Techedu Inc. American Depositary Shares

GOTU

Gaotu Techedu shares are trading higher after the company reported a year-over-year increase in Q1 sales results.

Needham analyst Ryan Koontz reiterates Extreme Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXTR#NASDAQ">EXTR</a>) with a Buy and maintains $20 price target.

Price Target

Reiteration

EXTR

Needham Reiterates Buy on Extreme Networks, Maintains $20 Price Target

PAVmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAVM#NASDAQ">PAVM</a>) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.13) by 46.15 percent. This is a 92.93 percent increase over losses of $(0.99) per share from the same period last year. The company reported quarterly sales of $8.00 thousand which missed the analyst consensus estimate of $10.00 thousand by 20.00 percent. This is a 99.21 percent decrease over sales of $1.01 million the same period last year.

PAVM

PAVmed Q1 Adj. EPS $(0.07) Beats $(0.13) Estimate, Sales $8.00K Miss $10.00K Estimate

Bitcoin Depot (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTM#NASDAQ">BTM</a>) reported quarterly earnings of $0.20 per share. This is a 180 percent increase over losses of $(0.25) per share from the same period last year. The company reported quarterly sales of $164.23 million which beat the analyst consensus estimate of $151.67 million by 8.28 percent. This is a 18.54 percent increase over sales of $138.54 million the same period last year.

Bitcoin Depot Q1 EPS $0.20 Up From $(0.25) YoY, Sales $164.23M Beat $151.67M Estimate

DeFi Development Corp. (NASDAQ:<a href="https://www.benzinga.com/stock/DFDV#NASDAQ">DFDV</a>) (the "Company") announced today the purchase of 16,447 Solana ("SOL") at an average price of $139.66 representing a total cost of approximately $2.3 million. At current market prices, the value of the purchased SOL is approximately $2.9 million.
This marks the Company's 11th SOL purchase under its crypto treasury strategy. Following this transaction, DeFi Development Corp. now holds a total of 609,190 SOL, valued at approximately $107 million — the largest SOL position of any publicly traded company.

DFDV

DeFi Development Purchases 16,447 Solana At Average Price Of $139.66 Representing Total Cost Of About $2.3M

Analysts' ratings for Americold Realty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COLD#NYSE">COLD</a>) over the last quarter vary from bullish to bearish, as provided by 5 analysts.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $23.2, a high estimate of $28.00, and a low estimate of $20.00. A decline of 12.45% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1747310515_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Americold Realty Trust. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Greg McGinniss</td>
<td>Scotiabank</td>
<td>Announces</td>
<td>Sector Perform</td>
<td>$20.00</td>
<td>-</td>
</tr>
<tr>
<td>Greg McGinniss</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Outperform</td>
<td>$24.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Anthony Powell</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$21.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Nick Joseph</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$23.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Greg McGinniss</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$28.00</td>
<td>$27.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Americold Realty Trust. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Americold Realty Trust compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Americold Realty Trust's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Americold Realty Trust's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/COLD/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Americold Realty Trust analyst ratings.</a>
<h2>All You Need to Know About Americold Realty Trust</h2>
Americold Realty Trust Inc is the world's second-largest owner and operator of temperature-controlled warehouses behind privately held Lineage Logistics. The Atlanta, Georgia-based firm owns and operates approximately 239 temperature-controlled warehouses, spanning 1.4 billion cubic feet. In 2022, the firm derived more than 80% of its revenue from the United States but also has sizable operations in Europe, Canada, Australia, and New Zealand. Americold supplements its core business by providing supply management and transportation services to its various customers. It operates as a real estate investment trust.
<h3>Key Indicators: Americold Realty Trust's Financial Health</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Decline in Revenue: Over the 3M period, Americold Realty Trust faced challenges, resulting in a decline of approximately -5.41% in revenue growth as of 31 March, 2025. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Real Estate sector.
Net Margin: Americold Realty Trust's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -2.6%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Americold Realty Trust's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -0.51%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Americold Realty Trust's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -0.21%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Americold Realty Trust's debt-to-equity ratio is below the industry average. With a ratio of 1.24, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: What Are They?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Where Americold Realty Trust Stands With Analysts

Ratings for Sweetgreen (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SG#NYSE">SG</a>) were provided by 16 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">4</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $29.38, a high estimate of $45.00, and a low estimate of $20.00. A 17.52% drop is evident in the current average compared to the previous average price target of $35.62. 
<img src="https://www.benzinga.com/files/images/story/2025/1747310493_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The analysis of recent analyst actions sheds light on the perception of Sweetgreen by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew Charles</td>
<td>TD Securities</td>
<td>Maintains</td>
<td>Buy</td>
<td>$25.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Rahul Krotthapalli</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$20.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Christine Cho</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$23.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Brian Bittner</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$29.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Brian Harbour</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$22.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Brian Mullan</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$20.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Rahul Krotthapalli</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$25.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Dennis Geiger</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$30.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Jon Tower</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$39.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Dennis Geiger</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$35.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Logan Reich</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$30.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Christine Cho</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$32.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Aisling Grueninger</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$27.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Brian Bittner</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$35.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>Andrew Charles</td>
<td>TD Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$33.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Logan Reich</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$45.00</td>
<td>$45.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Sweetgreen. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Sweetgreen compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Sweetgreen's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Sweetgreen's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/SG/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Sweetgreen analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Delving into Sweetgreen's Background</h2>
Sweetgreen Inc is a mission-driven, next-generation restaurant and lifestyle brand that serves healthy food at scale. Its bold vision is to be as ubiquitous as traditional fast food, but with the transparency and quality that consumers increasingly expect. It is creating plant-forward, seasonal, and earth-friendly meals from fresh ingredients and produce that prioritizes organic, regenerative, and local sourcing.
<h3>Sweetgreen: A Financial Overview</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Over the 3M period, Sweetgreen showcased positive performance, achieving a revenue growth rate of 5.36% as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Consumer Discretionary sector.
Net Margin: Sweetgreen's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -15.06%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Sweetgreen's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -5.7%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Sweetgreen's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -2.96%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Sweetgreen's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.76.
<h2>The Basics of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Demystifying Sweetgreen: Insights From 16 Analyst Reviews

TSHA

Taysha Gene Therapies Q1 EPS $(0.08) Beats $(0.09) Estimate, Sales $2.30M Beat $1.71M Estimate

Uber Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>) on Wednesday disclosed a strategic partnership with iFood to enhance <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/b45418279/uber-and-ifood-announce-strategic-partnership-in-brazil" rel="noreferrer noopener">convenience for millions of Brazilian consumers</a>.
This collaboration will enable iFood users to book Uber rides directly through the iFood application, while Uber users will gain access to iFood&#8217;s delivery services for food, groceries, pharmacy items, and convenience goods within the Uber app.
This collaboration intends to make everyday tasks easier for Brazilians by providing access to both transportation and delivery services within two of their most frequently used apps.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/downgrades/25/05/45298819/uber-downgraded-as-analyst-sees-fewer-near-term-catalysts-after-strong-run" rel="noreferrer noopener">Uber Downgraded As Analyst Sees Fewer Near-Term Catalysts After Strong Run</a>
The rollout of integrated Uber and iFood services will begin in selected Brazilian cities in the second half of 2025, with a country-wide expansion to follow.
Uber&#8217;s current delivery options for businesses (Uber Direct) and parcels (Uber Flash) will continue to operate as they do now through the Uber app, utilizing Uber&#8217;s drivers and couriers.
Likewise, iFood&#8217;s delivery support for its restaurant and other partners, along with its &#8216;Sob Demanda&#8217; service for deliveries initiated outside the iFood app, will not undergo any changes due to this partnership.
Dara Khosrowshahi, CEO of Uber, said, &#8220;Today, only around half of iFood and Uber customers in Brazil use both platforms. So this partnership represents a big milestone in our mission to help people go anywhere and get anything at the tap of a button.&#8221;
&#8220;Now, this integration represents a major step forward, with both companies innovating to offer a new way to access everyday services. We believe this partnership will drive more orders for restaurants, grocery stores, pharmacies, and convenience retailers; generate more income for couriers and drivers; and make consumers&#8217; everyday lives even easier,&#8221; added Diego Barreto, CEO of iFood.
Earlier in May, Uber reported&nbsp;fiscal first-quarter 2025 revenue growth of 14% year-on-year to $11.53 billion, missing the&nbsp;analyst consensus estimate of $11.62 billion and adjusted EPS of 83 cents, which beat the&nbsp;analyst <a target="_blank" href="https://www.benzinga.com/news/earnings/25/05/45252907/uber-sees-strong-trip-growth-but-warns-on-us-rideshare-pressure-in-2025-outlook" rel="noreferrer noopener">consensus estimate&nbsp;of 50 cents.</a>
Investors can gain exposure to the stock via iShares Trust iShares U.S. Transportation ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/IYT#BATS">IYT</a>) and&nbsp;The Advisors Inner Circle Fund Cambiar Aggressive Value ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAMX#NYSE">CAMX</a>).
Price Action: UBER shares are down 1.28% at $89.25 premarket at the last check on Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/05/45414625/aurora-innovation-shares-fall-as-uber-announces-1b-note-offering-whats-going-on" target="_blank" rel="noreferrer noopener">Aurora Innovation Shares Fall As Uber Announces $1B Note Offering: What&#8217;s Going On?</a></li>
</ul>
Image by DenPhotos via Shutterstock

Equities

Large Cap

Movers

Tech

CAMX

iShares Dow Jones Transportation Average Index Fund

UBER

Uber, iFood Unite In Brazil To Offer One-Stop App Convenience

Throughout the last three months, 4 analysts have evaluated Mattel (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAT#NASDAQ">MAT</a>), offering a diverse set of opinions from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $22.5, a high estimate of $30.00, and a low estimate of $17.00. Surpassing the previous average price target of $22.25, the current average has increased by 1.12%.
<img src="https://www.benzinga.com/files/images/story/2025/1747310472_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The analysis of recent analyst actions sheds light on the perception of Mattel by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Baker</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Buy</td>
<td>$30.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Stephen Laszczyk</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$21.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>James Hardiman</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$22.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Megan Alexander</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$17.00</td>
<td>$16.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Mattel. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Mattel compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Mattel's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Mattel's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/MAT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Mattel analyst ratings.</a>
<h2>Unveiling the Story Behind Mattel</h2>
Mattel manufactures and markets toy products that are sold to its wholesale customers and direct to retail consumers. The company offers products for children and families, including toys for infants and preschoolers, girls and boys, youth electronics, hand-held and other games, puzzles, educational toys, media-driven products, and plush and fashion-related toys. Mattel's owned portfolio includes Barbie, Hot Wheels, Fisher-Price, Thomas &amp; Friends, and American Girl. In addition, it currently manufactures toy products for its segments both internally and externally (through manufacturing partners). Nearly 60% of its net sales were generated from North America in 2024, with the remainder stemming from international markets.
<h3>Mattel: Delving into Financials</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: Over the 3M period, Mattel showcased positive performance, achieving a revenue growth rate of 2.11% as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Consumer Discretionary sector.
Net Margin: Mattel's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -4.88%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Mattel's ROE stands out, surpassing industry averages. With an impressive ROE of -1.84%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Mattel's ROA stands out, surpassing industry averages. With an impressive ROA of -0.63%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Mattel's debt-to-equity ratio surpasses industry norms, standing at 1.26. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>The Significance of Analyst Ratings Explained</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Where Mattel Stands With Analysts

4 analysts have shared their evaluations of Endava (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAVA#NYSE">DAVA</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $33.5, along with a high estimate of $50.00 and a low estimate of $18.00. Observing a downward trend, the current average is 16.25% lower than the prior average price target of $40.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1747310458_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The analysis of recent analyst actions sheds light on the perception of Endava by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mayank Tandon</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$18.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Jonathan Lee</td>
<td>Guggenheim</td>
<td>Lowers</td>
<td>Buy</td>
<td>$28.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>James Friedman</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Positive</td>
<td>$50.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Mayank Tandon</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$38.00</td>
<td>$43.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Endava. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Endava compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Endava's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Endava's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/DAVA/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Endava analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Get to Know Endava Better</h2>
Endava is a next-generation IT services company that primarily assists clients with their digital transformation efforts by creating customized software for them. The company was founded in 2006 in the U.K. and it continues to generate the majority of revenue in the U.K. and Europe. Endava's client base is concentrated in the payments and financial services, technology, media, and telecom industries.
<h3>Endava's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3M period, Endava showcased positive performance, achieving a revenue growth rate of 6.56% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Information Technology sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 3.5%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Endava's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 1.07%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Endava's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 0.7%, the company showcases efficient use of assets and strong financial health.
Debt Management: Endava's debt-to-equity ratio is below the industry average at 0.27, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: What Are They?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

DAVA

Beyond The Numbers: 4 Analysts Discuss Endava Stock

In the latest quarter, 6 analysts provided ratings for Alcoa (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AA#NYSE">AA</a>), showcasing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Alcoa and provided 12-month price targets. The average target is $31.5, accompanied by a high estimate of $47.00 and a low estimate of $25.00. This current average represents a 30.31% decrease from the previous average price target of $45.20. 
<img src="https://www.benzinga.com/files/images/story/2025/1747310444_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A clear picture of Alcoa's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Daniel Major</td>
<td>UBS</td>
<td>Announces</td>
<td>Neutral</td>
<td>$31.00</td>
<td>-</td>
</tr>
<tr>
<td>Bill Peterson</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$25.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Curt Woodworth</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$32.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Bill Peterson</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$28.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Lawson Winder</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$26.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Curt Woodworth</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$47.00</td>
<td>$53.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Alcoa. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Alcoa compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Alcoa's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Alcoa's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/AA/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Alcoa analyst ratings.</a>
<h2>Delving into Alcoa's Background</h2>
Alcoa is a vertically integrated aluminum company whose operations include bauxite mining, alumina refining, and manufacturing primary aluminum. It is the world's largest bauxite miner and alumina refiner by production volume, and the eighth-largest aluminum producer. Profits are closely tied to prevailing commodity prices along the aluminum supply chain.Alcoa was the first mass producer of aluminum, launching the world-changing Hall-Heroult smelting process in the 1880s, making aluminum affordable. It listed as a public company in 1925. In 2016, Alcoa spun off its automotive and aerospace metal parts segment to focus on mining, smelting, and refining. It bought the 40% unowned balance of AWAC in mid-2024, meaning refining assets are now predominantly wholly owned, as with smelting.
<h3>Alcoa: Delving into Financials</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Alcoa's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 29.63% as of 31 March, 2025, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Materials sector.
Net Margin: Alcoa's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 16.27% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Alcoa's ROE stands out, surpassing industry averages. With an impressive ROE of 9.99%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Alcoa's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 3.83%, the company showcases efficient use of assets and strong financial health.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 0.46, caution is advised due to increased financial risk.
<h2>What Are Analyst Ratings?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What Analysts Are Saying About Alcoa Stock

E.W. Scripps Partners With Freewheel To Increase Advertiser Investment Across Women's Sports and Live Events Including WNBA And NWSL

5 analysts have expressed a variety of opinions on Hasbro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HAS#NASDAQ">HAS</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $77.6, a high estimate of $84.00, and a low estimate of $72.00. This upward trend is evident, with the current average reflecting a 2.11% increase from the previous average price target of $76.00.
<img src="https://www.benzinga.com/files/images/story/2025/1747310420_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The perception of Hasbro by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Keegan Cox</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$75.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>James Hardiman</td>
<td>Citigroup</td>
<td>Announces</td>
<td>Buy</td>
<td>$72.00</td>
<td>-</td>
</tr>
<tr>
<td>Linda Bolton Weiser</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Neutral</td>
<td>$75.00</td>
<td>$73.00</td>
</tr>
<tr>
<td>Megan Alexander</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$84.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Eric Handler</td>
<td>Roth MKM</td>
<td>Raises</td>
<td>Buy</td>
<td>$82.00</td>
<td>$68.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Hasbro. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Hasbro compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Hasbro's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Hasbro's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/HAS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Hasbro analyst ratings.</a>
<h2>Unveiling the Story Behind Hasbro</h2>
Hasbro is a branded play company providing children and families around the world with entertainment offerings based on a world-class brand portfolio. From toys and games to television programming, motion pictures, and a licensing program, Hasbro reaches customers by leveraging its well-known brands such as Transformers, Nerf, and Magic: The Gathering. The firm acquired EOne in 2019, bolting on popular family properties like Peppa Pig and PJ Masks, and since has divested noncore lines from the tie-up. Furthermore, the addition of Dungeons &amp; Dragons Beyond in 2022, offers the firm access to 19 million digital tabletop players.
<h3>Breaking Down Hasbro's Financial Performance</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: Over the 3M period, Hasbro showcased positive performance, achieving a revenue growth rate of 17.14% as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Consumer Discretionary sector.
Net Margin: Hasbro's net margin excels beyond industry benchmarks, reaching 11.11%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Hasbro's ROE excels beyond industry benchmarks, reaching 8.47%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Hasbro's ROA excels beyond industry benchmarks, reaching 1.59%. This signifies efficient management of assets and strong financial health.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 2.87, caution is advised due to increased financial risk.
<h2>Analyst Ratings: Simplified</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Forecasting The Future: 5 Analyst Projections For Hasbro

RCAT

Red Cat Holdings shares are trading lower after the company reported worse-than-expected Q1 financial results.

Health Care

Press Releases

Theriva™ Biologics Announces U.S. FDA Guidance on Design of Phase 3 Study of VCN-01 for the Treatment of Metastatic Pancreatic Cancer

Theriva™ Biologics to Participate in the Q1 Investor Summit Virtual

Theriva™ Biologics Reports Full-Year 2024 Operational Highlights and Financial Results

General

Theriva™ Biologics to Present at the 2025 NeauxCancer Conference

Theriva™ Biologics Announces Positive Outcomes from the Second Meeting of the Independent Data Monitoring Committee for VIRAGE, the Company's Phase 2b Clinical Trial of VCN-01 in Combination with Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

Theriva Biologics Announces Presentation of Data from the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

Theriva™ Biologics Announces Primary Endpoints for Efficacy and Safety Achieved in VIRAGE Phase 2b Clinical Trial of VCN-01 with Gemcitabine/nab-Paclitaxel in Newly-Diagnosed Metastatic Pancreatic Cancer Patients

Theriva Biologics Announces Pricing of $7.5 Million Public Offering

Financing

Theriva Biologics Announces Closing of $7.5 Million Public Offering

Theriva™ Biologics Reports First Quarter 2025 Operational Highlights and Financial Results

TOVX

Aditxt

Apollomics

Aptevo Therapeutics

Bone Biologics

Entero Therapeutics

Genprex

GRI Bio

Pasithea Therapeutics Corp. - Common Stock

Pasithea Therapeutics

NuCana

Onconetix

Psyence Biomedical Ltd. - Ordinary Shares

Psyence Biomedical

Polyrizon

Protagenic Therapeutics, Inc. - Common Stock

Protagenic Therapeutics

Scinai Immunotherapeutics Ltd. - American Depositary Shares

Scinai Immunotherapeutics

Shuttle Pharmaceuticals Holdings, Inc. - common stock

Shuttle Pharmaceuticals

Salarius Pharmaceuticals, Inc. - Common Stock

Salarius Pharmaceuticals

Tharimmune

ZyVersa Therapeutics, Inc. - Common Stock

ZyVersa Therapeutics

Screenshot 2024-08-23 at 5.34.20 PM

Biotech

Theriva Biologics Receives Rare Pediatric Drug Designation From FDA For Treatment Of Retinoblastoma

Screenshot 2024-07-31 at 5.25.33 PM

Theriva Biologics Advances Its Product Pipeline To Improve Survival Rates For Many Difficult-To-Treat Cancers

Screenshot 2024-07-08 at 2.14.39 PM

Disproportionate Rise In Pancreatic Cancer Among Young Women Highlights High Unmet Need To Find Safe, Effective Treatments – Is Hope On The Horizon?

Screenshot 2024-06-06 at 5.27.01 PM

Theriva Biologics Receives Fast Track Designation From FDA For VCN-01 For Treating Metastatic Pancreatic Cancer

Screenshot 2024-04-16 at 5.31.31 PM

Theriva Biologics Hits Several Milestones In 2023, Positioning Itself For Growth As The Firm Targets Difficult-To-Treat Cancers

Screenshot 2024-03-26 at 11.16.22 PM

Utilizing Common Viruses To Combat Dangerous Cancers – Hear From The Leaders Of This Biotech

Screenshot 2024-03-13 at 5.34.18 PM

How Theriva Biologics Is Using An Adenovirus To Develop A Novel Treatment For Pancreatic Cancer, As Well As Other Cancers With An Unmet Need

Screenshot 2024-03-05 at 6.31.45 PM

CADL

CGON

CLDI

Could This Common Virus Unlock New Cancer Treatments? Theriva Biologics Believes That Adenoviruses Could Be Instrumental In The Next Evolution Of Oncology

Screenshot 2024-02-28 at 6.54.06 PM

For The First Time The US Is Set To Hit 2 Million New Cancer Cases: Theriva Biologics Presents Novel Solutions To The Deadliest Cancers

Comments

Theriva Biologics

ニュース

最新ニュース Theriva Biologics (AMEX:TOVX) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル